Liver Inflammation
11
3
4
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
9%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
LivQ-box® Parameters in the Diagnosis of Liver Inflammation
Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference
Endoscopic Ultrasound Guided Liver Biopsy and Portal Pressure Registry
Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs
sCD163 in PBC Patients - Assessment of Treatment Response
sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.
Simplified Monitoring Myanmar SM2 Study
Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B
Ultrasound Based Acoustic Radiation Force Impulse Imaging